Meeting
2013 Genitourinary Cancers Symposium
Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.
Authors
Giuseppe Procopio
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Giuseppe Procopio , Elena Verzoni , Sergio Bracarda , Sergio Ricci , Laura Ridolfi , Cosimo Sacco , Rosalba Miceli , Camillo Porta , Marco Bregni , Emilio Bajetta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT00609401
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 356)
DOI
10.1200/jco.2013.31.6_suppl.356
Abstract #
356
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Proton-pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
First Author: Aly-Khan A. Lalani
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff
Poster
2014 Genitourinary Cancers Symposium
Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy.
First Author: Seiichiro Ozono
Poster
2013 Genitourinary Cancers Symposium
Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States.
First Author: Sumanta Kumar Pal